This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neoplasms of Head & Neck  • Salivary Gland Disorders  • Alert me on articles by topic

The Mayo Clinic Experience

Derek Kofi O. Boahene, MD; Kerry D. Olsen, MD; Jean E. Lewis, MD; A. Daniel Pinheiro, MD; Vernon Shane Pankratz, PhD; Stephanie M. Bagniewski

Arch Otolaryngol Head Neck Surg. 2004;130:849-856.

Objective  To determine clinical and histopathologic features of mucoepidermoid carcinoma of the parotid gland, specifically, the relation of tumor stage and grade and treatment type with clinical outcome.

Design  Retrospective clinical and histopathologic review.

Setting  Tertiary care medical center.

Patients  From 1940 to 1994, 128 patients were treated at our institution for parotid mucoepidermoid carcinoma. Eighty-nine of these patients had their first treatment at our institution; these cases were chosen for retrospective clinical and histopathologic review.

Intervention  A head and neck pathologist independently reviewed the pathology specimens.

Main Outcome Measures  Age, symptoms, stage, treatment type, tumor grade, pathological features, disease progression, and survival.

Results  Results of clinical staging were: T1 in 56 patients, T2 in 13, T3 in 1, T4 in 15, N0 in 85, N1 in 2, and N2 in 2. No patient had N3 or M1 disease. All patients underwent parotidectomy with or without neck dissection. Seven patients received postoperative radiotherapy. Tumor grade was low in 43 patients (48%), intermediate in 40 (45%), and high in 6 (7%). Only 5 patients had disease progression (local recurrence in 4, regional recurrence in 4, and distant recurrence in 2). At latest follow-up (mean follow-up, 14.7 years), 64 patients were alive without disease, 1 was alive with disease, 2 had died of mucoepidermoid carcinoma, and 22 had died of other causes. The Kaplan-Meier estimated cancer-specific survival rates at 5, 15, and 25 years were 98.8%, 97.4%, and 97.4%, respectively.

Conclusions  In our study, tumor grade and stage appeared to be less important than previously described. With adequate parotidectomy and appropriate neck dissection, patients with mucoepidermoid carcinoma of the parotid gland appear to do well, with few recurrences.

From the Departments of Otorhinolaryngology (Drs Boahene and Olsen) and Laboratory Medicine and Pathology (Dr Lewis) and the Division of Biostatistics (Dr Pankratz and Ms Bagniewski), Mayo Clinic, Rochester, Minn, and the Greater Baltimore Head & Neck Associates, Baltimore, Md (Dr Pinheiro). The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mucoepidermoid Carcinoma of the Head and Neck: Clinical Analysis of 43 Patients
Ozawa et al.
Jpn J Clin Oncol 2008;38:414-418.
ABSTRACT | FULL TEXT  

Mucoepidermoid carcinoma of the parotid gland in children: A 10-year experience.
Rahbar et al.
Arch Otolaryngol Head Neck Surg 2006;132:375-380.
ABSTRACT | FULL TEXT